On May 10, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reported participation at upcoming industry conferences (Press release, Immutep, MAY 10, 2019, View Source [SID1234536213]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference:
New York Academy of Sciences, Frontiers in Immunotherapy

Dates:
May 14-15, 2019

Venue:
The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York, USA

Participation:
Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion titled "Novel Approaches from Biotech"

Conference:
World Advanced Therapies & Regenerative Medicine Congress & Expo 2019

Dates:
May 15-17, 2019

Venue:
Business Design Centre, London, UK

Presentation Title:
Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials

Presenter:
Frédéric Triebel, CSO & CMO of Immutep

Conference:
American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting

Dates:
May 31 – June 4, 2019

Venue:
McCormick Place, Chicago, IL, USA

Abstract Number and Title: TPS2667, "A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC)."

Poster Session: Developmental Immunotherapy and Tumor Immunobiology

Session Data and Time: Saturday, Jun 1, 8:00 – 11:00 a.m. CDT

Location: Hall A, Poster Board Number: #299b

Abstract Number and Title: TPS2651, "The "INSIGHT" Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities."

Poster Session: Developmental Immunotherapy and Tumor Immunobiology

Session Data and Time: Saturday, Jun 1, 8:00 – 11:00 a.m. CDT

Location: Hall A, Poster Board Number: #291b